TABLE 1.

Patient Characteristics

Patient	Age (y)	HER2 status in primary tumor before imaging (IHC/FISH)	HER2 gene amplification (determined after imaging)	Primary tumor status (ER/PgR)	Clinical stage before imaging
1,000 μg; mean tumor size, 28 ± 11 mm
1	68	1+ (IHC)	FISH-	ER+/PgR-	IIA (T2N0M0)
2	62	1+ (IHC)	FISH-	ER+/PgR+	I (T1N0M0)
3	66	1+ (IHC)	FISH-	ER+/PgR+	IIA (T2N0M0)
4	48	0 (IHC)	FISH-	ER-/PgR-	IIA (T2N0M0)
5	50	3+ (IHC)	FISH+	ER+/PgR+	IIA (T2N0M0)
6	70	3+ (IHC)	FISH-	ER+/PgR+	IIA (T2N0M0)
7	30	3+ (IHC)	FISH+	ER+/PgR+	IIB (T2N1M0)
8	59	2+ (IHC)/FISH+		ER-/PgR-	IIA (T2N0M0)
9	45	(IHC)3+	FISH-	ER+/PgR-	IIB (T2N1M0)
2,000 μg; mean tumor size, 25 ± 6 mm
10	50	1+ (IHC)	FISH-	ER+/PgR+	IIA (T2N0M0)
11	57	1+ (IHC)	FISH-	ER+/PgR+	I (T1N0M0)
12	43	1+ (IHC)	FISH-	ER+/PgR+	IIA (T2N0M0)
13	51	1+ (IHC)	FISH-	ER-/PgR-	IIA (T2N0M0)
14	65	3+ (IHC)	FISH+	ER+/PgR+	IIA (T2N0M0)
15	35	3+ (IHC)	FISH+	ER+/PgR+	I (T1N0M0)
16	50	1+ (IHC)*	FISH+	ER+/PgR+	IIA (T2N0M0)
17	68	2+ (IHC)/FISH+		ER+/PgR-	IIA (T2N0M0)
18	68	3+ (IHC)	FISH+	ER+/PgR+	IIA (T2N0M0)
3,000 μg; mean tumor size 22 ± 7 mm
19	37	1+ (IHC)	FISH-	ER-/PgR-	IIA (T2N0M0)
20	45	1+ (IHC)	FISH-	ER+/PgR+	IIA (T2N0M0)
21	56	1+ (IHC)	FISH-	ER+/PgR+	IIA (T2N0M0)
22	45	1+ (IHC)	FISH-	ER+/PgR+	IIA (T2N0M0)
23	36	1+ (IHC)	FISH-	ER+/PgR+	IIA (T2N0M0)
24	48	3+ (IHC)	FISH+	ER+/PgR+	IIВ (T2N1M0)
25	58	3+ (IHC)	FISH+	ER+/PgR+	IIA (T2N0M0)
26	47	1+ (IHC)*	FISH+	ER+/PgR+	IIA (T2N0M0)
27	61	3+ (IHC)	FISH+	ER+/PgR-	IV (T4N3M1)
28	49	3+ (IHC)	FISH+	ER+/PgR+	I (T1N0M0)

^*Postimaging FISH evaluation demonstrated HER2 gene amplification.

IHC = immunohistochemistry; ER = estrogen receptor; PgR = progesterone receptor;+ = positive; - = negative.